ALGLUCERASE - A REVIEW OF ITS THERAPEUTIC USE IN GAUCHERS-DISEASE

被引:27
作者
WHITTINGTON, R
GOA, KL
机构
[1] Adis International Limited, Auckland, 41 Centorian Drive, Mairangi Bay
关键词
D O I
10.2165/00003495-199244010-00007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Alglucerase is a mannose-terminated form of human placental glucocerebrosidase, developed to treat patients with Gaucher's disease. Functional glucocerebrosidase is deficient in Gaucher's disease, an autosomal recessive lipid storage disorder that affects people of all ethnic backgrounds, but has a higher incidence among East European Jews (Ashkenazim). Gaucher's disease manifests with hepatosplenomegaly, bleeding disorders and bone disease, with the more rare subtypes (types 2 and 3) featuring neurological dysfunction. Prior to the development of enzyme replacement therapy, treatment for Gaucher's disease was mainly symptomatic relief Primary treatment with glucocerebrosidase focuses on removal of the lipid metabolite that causes the pathology. Because of the rarity of Gaucher's disease clinical trials are small, and much of the data investigating alglucerase therapy have been obtained from studies of patients with type 1 disease, the prevalent subtype. Nonetheless, after intravenous administration of alglucerase, improvements are evident within 6 months of therapy. Patients have increased haemoglobin levels and platelet counts, and decreased incidences of epistaxis and bruising. Spleen and liver size are reduced, and skeletal parameters improve. Children gain height and most patients receiving alglucerase therapy are able to resume work and daily activities. Alglucerase is well tolerated, with few mild adverse reactions reported. Although the pharmacokinetic and pharmacodynamic information for alglucerase is limited, its unequivocal efficacy justifies enzyme replacement therapy with this compound as first-line treatment for patients with Gaucher's disease, for whom treatment options are limited.
引用
收藏
页码:72 / 93
页数:22
相关论文
共 91 条
  • [51] ACID BETA-GLUCOSIDASE - ENZYMOLOGY AND MOLECULAR-BIOLOGY OF GAUCHER DISEASE
    GRABOWSKI, GA
    GATT, S
    HOROWITZ, M
    [J]. CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1990, 25 (06) : 385 - 414
  • [52] GRIBBLE TJ, 1991, 8TH INT C HUM GEN
  • [53] GROTH CG, 1971, LANCET, V1, P1260
  • [54] HARDY B, 1987, BIOMED PHARMACOTHER, V41, P40
  • [55] HENDERSON JM, 1991, AM J GASTROENTEROL, V86, P346
  • [56] JAMES SP, 1981, GASTROENTEROLOGY, V80, P126
  • [57] BIOSYNTHESIS AND MATURATION OF GLUCOCEREBROSIDASE IN GAUCHER FIBROBLASTS
    JONSSON, LMV
    MURRAY, GJ
    SORRELL, SH
    STRIJLAND, A
    AERTS, JFGM
    GINNS, EI
    BARRANGER, JA
    TAGER, JM
    SCHRAM, AW
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1987, 164 (01): : 171 - 179
  • [58] GAUCHER CELLS IN CHRONIC MYELOCYTIC LEUKEMIA - AN ACQUIRED ABNORMALITY
    KATTLOVE, HE
    WILLIAMS, JC
    GAYNOR, E
    SPIVACK, M
    BRADLEY, RM
    BRADY, RO
    [J]. BLOOD-THE JOURNAL OF HEMATOLOGY, 1969, 33 (2P2): : 379 - &
  • [59] TYPE-2 AND TYPE-3 GAUCHER DISEASE - A MORPHOLOGICAL AND BIOCHEMICAL-STUDY
    KAYE, EM
    ULLMAN, MD
    WILSON, ER
    BARRANGER, JA
    [J]. ANNALS OF NEUROLOGY, 1986, 20 (02) : 223 - 230
  • [60] Kolodny EH, 1982, GAUCHER DISEASE CENT, P33